Serotonin, how to find it... by Crespi, Francesco
Xjenza Online - Journal of Malta Chamber of Scientists
http://www.mcs.org.mt/
Doi: http://dx.medra.org/10.7423/XJENZA.2013.2.02
Review Article
Serotonin, how to find it...
Francesco Crespi1
1Neurosciences, GlaxoSmithKline, Via Fleming 4, 35135 Verona, Italy
Abstract. Serotonin or 5-hydroxytryptamine (5-
HT) is a monoamine neurotransmitter. Biochemically
derived from tryptophan, serotonin is primarily found
in the gastrointestinal tract, platelets, and in the
central nervous system (CNS) of animals, including
humans. Discovered and crystallized over sixty years
ago, serotonin operates as a short-range neurotrans-
mitter as well as a long-range signalling modulator,
with multiple effects on whole organism functions via
plasma, platelet and neuroendocrine, gut, adrenal
and other peripheral systems across many species.
All of the important functions of serotonin in the
brain and body were identified over the ensuing years
by neurochemical, physiological and pharmacological
investigations. Mainly, all these investigations have
been performed via invasive methodologies, particularly
in the CNS studies. Here we present a rapid overview
of such methodological approaches focussing on voltam-
metry, one of the most recent technical approaches for
serotonin analysis in vivo, in situ and in real time.
Furthermore, we introduce a late technical evolution in
the attempt to obtain in vivo non invasive measurement
of brain serotonin.
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1 Introduction
1.1 Serotonin
Serotonin (5-hydroxytryptamine; 5-HT) was initially
discovered as a vasoconstrictor substance in blood
and later in blood vessel walls, platelets and in ente-
rochromafine cells of the gastrointestinal system, the
lungs and the heart (Vialli et al. 1933; Rapport et
al. 1948; Peroutka et al. 1994). More than 50 years
ago the chemical structure of 5-HT was identified
and synthesised (Twarog et al. 1953). Later, the
function of 5-HT as a neurotransmitter in the CNS was
proposed (Bogdanski et al. 1956) and has been studied
intensively since its identification in the pituitary gland
(Hyyppa et al. 1973).
In the central nervous system (CNS) serotonin is
synthesised in the perikarya of the neuron where the
diet amino acid tryptophan is hydroxylated to the 5-HT
precursor 5-hydroxytryptophan (5-HTP), which is then
decarboxylated to 5-HT (Hamon et al. 1982). To avoid
immediate enzymatic oxidation to 5-hydroxy-indol
acetic acid (5-HIAA) by monoamine oxidase, 5-HT
is contained in neuronal vesicles until it is released
into the synaptic cleft. Serotonin then activates either
post-synaptic or pre-synaptic receptors or undergoes
reuptake via the 5-HT transporter molecule (Sert) into
the neuron (Hamon et al. 1982).
Serotonin is involved in regulation of the central neu-
roendocrine system as well as cognitive functions, mood
and basal physiological functions (Van de Kar 1991).
Dysfunction of the intra- and interneuronal 5-HT trans-
mitter systems may result in impairment of coping with
states of increased stress, cognitive dysfunction and
eventually mental diseases (Graeff et al. 1996; Roth et
al. 2004). Furthermore, the 5-HT system is involved in
regulation of gastrointestinal function and in the devel-
opment of diseases such as migraine, obesity and nausea
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Figure 1: Voltammetry: top: principle, middle: the voltammo-
gram obtained in vivo in the CNS when using DPV together with
μCFE; bottom: schematic drawing of the μCFE and its theoretical
positioning within the brain tissue [not to scale].
(Meguid et al. 2000; Saxena 1995).
1.2 5-HT distribution
5-HT distribution in the brain is diffuse and complex.
The location of 5-HT containing cell bodies in the CNS
was first shown by Dahlstrom et al. (1964) using the flu-
orescent histochemical technique introduced by Falk et
al. (1962). In 1981, an extremely detailed mapping of 5-
HT pathways in the CNS was performed using a specific
immunohistochemical technique (Steinbusch 1981).
1.3 5-HT cell bodies
The majority of cell bodies lie within the brain stem and
mesencephalon in nine groups labelled B1 to B9. Cell
bodies B1 to B4 and B6 are located in the medulla. The
B1-raphe pallidus, B2-raphe obscurus, B3-raphe mag-
nus and B4/B6-region exsisting under the 4th ventri-
cle. Group B5-cell bodies lie within the raphe dorsalis.
Finally, groups B8 and B9 are located in the mesen-
cephalon and lie within the raphe medianus and lemnis-
cus medialis respectively (Steinbusch 1981). 5-HT cell
bodies have also been reported by various authors in the
locus caeruleus and sub-caeruleus.
1.4 5-HT pathways
5-HT nerve terminals extend throughout the brain and
spinal cord (Steinbusch 1981). Briefly, the 5-HT inner-
vation of the brain can be divided into two main ascend-
ing axon bundles termed the medial and lateral ascend-
ing pathways (originating from cell bodies in B-5-6-7-
8-9) and descending bulbo-spinal neurones (originating
from the raphe nuclei of the medulla oblongata). The
main brain areas innervated by 5-HT neurones include
the thalamus, hypothalamus, subthalamus, olfactory ar-
eas, cortex, basal ganglia, septum, hippocampus and
substantia nigra.
2 Methods
2.1 5-HT release
In vitro studies of 5-HT release are limited by the rapid
re-uptake of released 5-HT, necessitating the presence of
an uptake inhibitor in the incubation medium (Black-
burn et al. 1967) and can only give an approximation
of actual in vivo amine levels as the complex cellular
and sub-cellular events in tissue cannot be duplicated
in vitro.
The first notable in vivo techniques developed for in
vivo analysis of 5-HT release are the technique of “push-
pull cannulae” (Gaddum, 1961) a perfusion -based tech-
nique, as well as “intracranial microdialysis” (Ungerst-
edt, 1984). These are two similar methods with major
limitations, briefly: i] excessive dimension of the probe
thus limiting the analysis to large brain areas with tis-
sue damage (Yaksh et al. 1974; Khan et al. 2003); ii]
all perfusion techniques make an indirect measurement
of release as they measure diffusion and not strictly re-
lease, with the chemicals collected being measured “off
line”. These methods also have quite a slow response
time, 10-30 min is needed to collect a volume of per-
fusate great enough to allow the detection of chemicals
within it. Their detection is thus not performed in “real
time” with, in consequence, a poor correlation between
changes in their extracellular levels, neuronal activity
and behaviour.
An alternative method is voltammetry: in 1924 Hey-
rovsky found that the current at a mercury electrode
was not directly proportional to the applied voltage, but
that there was the presence of an extra-current deter-
mined by the oxidisable chemicals present in the solu-
tion. Such extra-current, that is proportional to the con-
centration of the compound(s) oxidised and/or reduced,
is called polarographic current when obtained at a mer-
cury electrode, and voltammetric current when obtained
at all other types of electrode (Adams 1969 a,b). Differ-
ent types of voltammetric techniques are available, the
most common of which are chrono-amperometry linear
voltammetry, cyclic voltammetry, and pulse voltamme-
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Figure 2: Various types of voltammetric electrodes developed since the 1970s, from the first ones made of platinum wire or teflon coated
silver wire to the carbon paste based electrodes and finally to the carbon fibre electrodes (for a review: Stamford et al. 1992).
try. These methodologies are mainly based on the ap-
plication of a “dynamic” oxidation or oxido-reduction
potential and the resulting analysis of electrons “freed”
by the chemical(s) under analysis (Fig.(1.1).
Different types of voltammetric electrodes have been
developed since 1969, the most successful type appears
to be carbon based electrodes and in particular the car-
bon fibre micro electrodes (μCFE) see Fig.(2).
2.2 In vivo voltammetry
An advanced approach to monitoring changes in
monoamine release and their metabolism is the tech-
nique of in vivo voltammetry using micro biosensors,
mainly carbon-fibre micro electrodes (μCFE) with a 7
to 30 micrometer diameter (see Figs.(1, 2, 3)). The
method fulfils many of the criteria required to monitor
specific compounds in the extracellular fluid:
I- Measurements can be made in the extracellular fluid
of specific large as well as small brain nuclei with min-
imal damage to the nervous tissue and disturbance to
the animal due to the small dimensions of the probe
(see Figs.(1, 3)), which can sample an area of approx-
imately 10-6mm3. Thus there is a clear high anatomi-
cal resolution of the site of measurement within discrete
brain regions of rodents. Furthermore, no signs of the
presence of the micro electrode could be observed in the
brain tissue when the histological evaluations correct (or
incorrect) location of its active tip, within the brain re-
gion studied, was performed under light microscopy at
the end of each experiment when the brain was rapidly
removed and sectioned using a cryostat. This indicates
that the sole insertion of μCFE into the brain does not
produce tissue lesions detectable by light microscopy.
Indeed, a lesion (coagulated brain tissue) was necessary
and was obtained at the end of each experiment via ap-
plication of a direct current through the active tip of the
μCFE to verify such position under light microscopy in
brain slices stained using the NISSL solution. II- The
method allows rapid, repeated measurements with accu-
rate time resolution in vivo, in situ in real time without
recourse to perfusion based techniques or radiolabelled
transmitter stores, or the need for sample preparation
or chromatographic separation. This is the fundamen-
tal difference between voltammetry and perfusion tech-
niques (Crespi et al. 1988; Stamford et al. 1992).
III-In vivo voltammetry can be performed in conscious
freely moving animals. This, combined with points
I and II, avoids the problems associated with anaes-
thetics and allows correlations within neuronal activ-
ity behaviour. Furthermore, recent improvement in the
methodology allow voltammetric analysis in telemetric
– wireless conditions allowing electrochemical studies in
absolute freely moving conditions (Crespi 2010a) (see
Fig.(3)). Indeed, the enhanced telemetric system based
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Figure 3: In vivo voltammetry in conscious freely moving condi-
tions
Top left: magnification of the electro-active tip of the μCFE be-
fore (right) and after Nafion R©coating (left). Bar: 100μm.
Bottom right: the behaving freely moving rat with the trans-
mitter unit TX placed upon its head transmitting the signal via
an infrared channel to the receiving station (RX). The TX is a
miniaturised circuit (dimension of about 0.5cm3) of much reduced
weight (5–6g). It is mounted on the animal’s head and connected
to the voltammetric three-electrode system inserted into the brain.
A laptop computer, interfaced to the receiving station, performs
the required signal acquisition and analysis (top right).
Bottom left: representative in vitro DPV curves for dopamine
5μM and serotonin 5μM as measured with Nafion R©-μCFE (Crespi
et al. 1988). In vivo studies, the tip of the Nafion R©-μCFE is in-
serted in a discrete brain area, i.e. the rat prefrontal cortex as
shown by the red arrow in E. [With permission from Biosensors
and Bioelectronics].
on either differential pulse voltammetry (DPV) or direct
current amperometry (DCA) “diffused” via a single-way
infrared (IR) transmission channel is of much reduced
dimension and weight. In particular, parallel in vivo ex-
periments in rats prepared for classical wire-connected
DCA or for wireless DCA resulted in superimposed data
when the 5-HT system in the frontal cortex was chal-
lenged with fluoxetine (Crespi 2010a).
2.3 Biogenic amines or metabolites?
As introduced above, voltammetry in association with
specifically prepared micro-biosensors detects the cere-
bral extracellular content of neurotransmitters and re-
spective metabolites.
Pharmacological experiments have indeed demon-
strated that ascorbate, noradrenaline and/or dopamine
(and its metabolite DOPAC), 5-OH-indoles (i.e. sero-
tonin and its metabolite 5-HIAA) (Crespi 1990; Crespi
et al. 1988) uric acid, (Crespi et al. 1983b) homovanillic
acid, 3-methoxytyramine (Crespi et al. 1989b) as well as
Figure 4: The figure shows different compounds presenting
electro-active chemical groups so that they can be measurable
with voltammetry.
Figure 5: The voltammetric-electrophysiological set up consists
of the concomitant use of a potentiostat three-electrode system
(A: auxiliary, R: reference and the µ CFE) and an electrophysio-
logical two-electrode unit (G: ground electrode and the µ CFE).
Electrodes A, R and G were inserted between the bone and the
dura mater through holes (200µ m diameter) that were drilled
in the parietal bone. The µ CFEs were inserted in the specific
brain regions studied (i.e.amygdale [AMY] and raphe dorsalis nu-
cleus [RDN], respectively) under light microscopy. All electrodes
were connected with electrical wires to the polarograph or the
electrophysiological apparatus driven by specific softwares (GPES
Ecochemie, The Netherlands or MSD Alpha-Omega, Israel, re-
spectively).
neuropeptides containing electroactive amino acids such
as tryptophan, cysteine, tyrosine, (Crespi 1991, Crespi
2011) melatonin and (Crespi 2012; Crespi et al. 1994)
nitric oxide (Crespi et al. 2001; Rossetti et al. 2004),
can be selectively monitored with this methodology.
At one stage it was thought that in vivo voltamme-
try could be used to study BIOGENIC AMINES such
as DA, 5-HT release directly in situ and in real time
(Adams et al. 1978; Marsden et al. 1979). Later on,
however, it was determined that the voltammetric signal
in vivo was mainly correlated to the oxidation of extra-
cellular metabolites (Crespi et al. 1984) (see Fig.(4)).
The development of a new voltammetric biosensor
(the Nafion carbon fibre micro-electrode described in
Fig.(3)) made it possible to directly measure the release
of 5-HT in vivo (Crespi et al. 1988).
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Figure 6: Fluorescence intensity induced by LASER excitation
of solutions containing 5-HT nanoM or microM concentrated and
5-HIAA milliM concentrated versus water.
Figure 7: Typical histological pattern of the hippocampus con-
taining the pyramidal cell layer:
(a) Pyramidal 5-HTcells (PY): non stained section without exci-
tation AND
(b) Under excitation at 366nm, resulting in a similar pattern as
in (c):
(c) Pyramidal 5-HTcells (PY) stained with hematoxilin eosin,
bar=90μm.
Arrows indicate the same histological position.
2.4 Parallel electrochemical [voltam-
metric] and electrophysiological in
vivo studies
It has also beenshown that voltammetric analysis
of neurotransmitter release and metabolism can be
coupled with analysis of vigilance states via coupling
EEG, EOG and EMG recordings with electrochemical
[voltammetric] measurement. In particular, this ap-
proach has been very valuable for studying the putative
relationship between sleep-awake circadian rhythm and
serotonergic activity in the raphe regions of rodents;
i.e., demonstrating a direct relationship between sleep-
awake circadian rhythm and release of 5-HT in the
raphe nuclei (Crespi and Jouvet 1982), the brain region
involved in the regulation of such sleep-awake circadian
rhythm (Jacobs and Azmitia 1992; Ursin 2002).
The feasibility of concomitant in vivo recordings
of electrophysiological signals such as cell firing and
voltammetric measurements of unstimulated levels of
extracellular compounds has also been demonstrated ei-
ther with these two independent techniques combined in
vivo at a single electrode (Crespi 2002) or with parallel
recordings in cell bodies; i.e., dorsal raphe nucleus [elec-
trophysiology] and voltammetric recordings in related
Figure 8: Left: Excitation spectrum obtained in the rat hip-
pocampus homogenate following addition of exogenous 5-HT
1× 10−4M and after subtraction of the initial spectrum recorded
in the untreated hippocampus homogenate (0.5mg proteins/ml).
Right: Trend of the emission spectra (excitation 366 nm) mon-
itored in the hippocampus homogenate of untreated rat follow-
ing addition of exogenous 5-HT at concentrations 5 × 10−6M,
5×10−5M, 5×10−4M and 1×10−3M, respectively. Lowest curve
refers to the homogenate before 5-HT addition.
Figure 9: Concomitant fluorescence intensity (L.I.F.E. at 420-
470nm range) and DPV levels of endogenous 5-HT measured in
homogenates from the hippocampus or cortex obtained from rats
submitted to chronic fluoxetine (Left) or chronic stress (Right)
treatments. Data are expressed in percent of values from control
homogenates. Overall, no statistical differences were obtained
when comparing DPV results versus L.I.F.E. data using either
paired or unpaired T-Test or univariate test of significance over the
parameterised model (for further details see Crespi et al. 2004).
terminal regions or in the amygdala (Crespi 2009)(see
Fig.(5)). This verifies the original proposal that a com-
bined treatment with a potassium (SK) channel blocker
such as apamin and fluoxetine could overcome the slow
onset of the SSRI upon central 5-HT activity that could
be related to the slow onset of its therapeutic antide-
pressant action (Crespi 2010b). Electrochemical and
behavioural evidence of a direct relationship between
cerebral 5-HT and cytoskeleton in the control of mood
was also confirmed (Crespi 2010c). Concomitant be-
havioural and voltammetric analysis could also be per-
formed, proposing that divergent central serotonergic
activities may be responsible for either despair or learn-
ing behaviour in intact Wistar or Sprague-Dawley CD
rats, respectively (Crespi 2010d)
2.5 Serotonin measurements: from in-
vasive to non – invasive approaches
In 1962, Udenfriend showed that serotonin can act as
a fluorophore as its light-absorption and emission prop-
erties in aqueous solution occur in the near-UV-visible
region.
In 1979, Aubin showed the existence of an auto-
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Figure 10: In vivo NIRS: Top: block diagram of the NIRS prototype applied to rodents.
Bottom left: brain areas monitored using four sources and one receiver: computer simulation of photon paths based on photon
migration theory.
Bottom right: changes of physiological parameters following pure oxygen administration (for further details see Crespi 2007).
fluorescence emission in the UV-visible interval when
biological tissues were submitted to suitable light stim-
ulating conditions.
Based upon this evidence, in 1990 Crespi had pro-
posed the use of light-induced fluorescence excitation
(L.I.F.E.) in the attempt to selectively monitor neuro-
transmitters based upon analysis of their own fluores-
cence. This approach demonstrated that the autofluo-
rescence properties of a neurotransmitter such as sero-
tonin can be selectively evaluated (see Figs.(6, 7)). Then
L.I.F.E. spectroscopy was performed in ex vivo and in
vivo experiments: it was observed that serotonin ex-
hibited the well known excitation and emission bands
in the UV region (i.e. 250-320nm) and also other mi-
nor excitation and emission bands in the near UV re-
gion (i.e. 450-580nm). Furthermore, spectrofluorimet-
ric measurements under 366nm excitation performed
on solutions supplied with serotonin or on brain ho-
mogenates obtained from control or specifically treated
rats, were consistent with those obtained in parallel ex-
periments using in vitro or ex vivo voltammetry (see
Fig.(8)), therefore proposing the application of in vivo
L.I.F.E. Indeed, in vivo L.I.F.E. studies performed in
situ and in real time by means of 50μm diameter op-
tic fiber stereotaxically implanted in discrete brain ar-
eas of anaesthetised rats, again resulted consistent with
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Figure 11: Set-up of instrumentation for in-vitro fluorescence mea-
surements and Laser source spectrum: from near IR to near UV.
parallel in vivo voltammetric experiments performed in
rats treated with chemicals selectively affecting the 5-
HT system (Crespi et al. 2004) (see Fig.(9)).
However, this methodology as well as in vivo voltamme-
try, remains invasive.
In the attempt to overcome invasiveness, Near In-
frared Spectroscopy (NIRS) methodology was applied:
by means of prototype instrumentation for analysis in
small rodents (Fig.(10)). This technique allows non in-
vasive in vivo preclinical studies of CNS metabolic func-
tions via direct measurement of oxyhaemoglobin and de-
oxyhaemoglobin (Crespi 2007). In addition, it permits
the assessment of real time brain penetration and effi-
cacy of drug treatments (Crespi et al. 2006).
Therefore NIRS permits (as well as MRI) translational
strategy from preclinical to clinical investigations.
2.6 Laser source spectrum: from near
IR to near ultraviolet (UV)
Based on NIRS (i.e. non-invasive laser based method-
ology) is the actual attempt to use NON invasive spec-
troscopy to analyse neurotransmitter in the rat CNS.
The technical principle is the same described for the
NIRS study of brain metabolism, the main difference re-
lated to the source-receiver system needed for detecting
natural or induced fluorescence of endogenous chemicals
acting as neurotransmitters such as serotonin. For this
purpose, other types of sources have been taken into
consideration and in particular UV laser sources have
been selected such as the Hamamatsu M8903-01 that is a
pico-second light pulser with wavelength of 402 nm (near
UV wavelength spectrum: 300 to 400nm). It has been
combined with the Hamamatsu spectrometer H8353 and
a dedicated optical set-up (see Fig.(11)). This source
has first been tested using fluoresceine, a compound
known to have a spectrum of fluorescence within the
green band of the visible wavelength; i.e. 480-560nm.
Figure 12: Top: Fluoresceine emission spectra obtained with flu-
oresceine tested at various concentrations: emission intensity peak
[arbitrary units, U.A.] is monitored at 520nm;
Bottom: Experimental point of revealed intensity at 520nm as a
function of fluoresceine concentration.
To do so the Hamamatsu spectrometer H8353 has been
completely characterized using the optical set-up shown
in Fig.(11), in particular the cuvette contains a solution
with different concentrations of fluoresceine: from 10mi-
croM up to 100microM in order to test the linearity of
the receiving unit. The output beam of the laser source
has been collimated by means of a bi-convex lens with
focal length f=10 mm. Emission spectra of these fluo-
resceine concentrations are shown in Fig.(12) TOP, con-
firming the linearity of the receiving unit. The emission
intensity peak was obtained at 520nm and it appeared
that the increase in the emission intensity is related to
fluoresceine concentration as assessed in Fig.(12) BOT-
TOM, where the linearity error is 3.19% full-scale.
Based on the L.I.F.E. spectroscopy observations re-
ported above showing that serotonin exhibited also
other minor excitation and emission bands in the near
UV region, i.e. 450-580nm, experiments were performed
in the same conditions described for fluoresceine. The
preliminary data gathered, to be confirmed in further
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studies, indicate that 5-HT could be also monitored with
this set-up within the blue region. Different 5-HT con-
centrations were tested (1, 10 and 100 microM) and data
lead to meaningful differences in the intensity of the flu-
orescence spectra.
3 Concluding Remarks
In conclusion, non-invasive laser based NEAR UV
methodology is introducing very promising results on
the attempt to analyse auto-fluorescent neurotransmit-
ters, such as serotonin, using optic fibres in vivo and in
non-invasive conditions.
References
Adams R. N., Conti J., Marsden C. A., Strope, E.
(1978) The measurement of dopamine and 5-
hydroxytryptamine release in CNS of freely moving
rats. Br. J. Pharmacol. 64(3), 470P.
Adams R. N. (1969a) Application of modern electroana-
lytical techniques to pharmaceutical chemistry. J.
Pharm. Sci. 58(10), 1171 -1178.
Adams R. N. (1969b) Rapid voltage sweep methods at
stationary electrodes In Electrochemistry at Solid
Electrodes, Marcel Dekker, New York.
Aubin J. E. (1979) Autofluorescence of viable cultured
mammalian cells. J. Histochem. Cytochem. 27(1),
36-43.
Blackburn K. J., French P. C., Merrilis, R. J. (1967)
Serotonin uptake by rat brain in vitro. Life Sci. 6,
1653-1663.
Bogdanski D. F., Pletscher A., Brodie B. B., Udenfriend
S. (1956) Identification and assay of serotonin in
brain. J. Pharmacol. Exp.Ther. 117(1), 82-88.
Crespi F. (2012) Influence of melatonin or its antago-
nism on alcohol consumption in ethanol drinking
rats: a behavioural and in vivo voltammetric study.
Brain Res. 1452, 39-46.
Crespi F. (2011) Influence of Neuropeptide Y and an-
tidepressants upon cerebral monoamines involved
in depression: An in vivo electrochemical study.
Brain Res. 1407, 27-37.
Crespi F. (2010a) Wireless in vivo voltammetric mea-
surements of neurotransmitters in freely behaving
rats. Biosens. and Bioelectr. 25, 2425–2430.
Crespi F. (2010b) SK channel blocker apamin attenu-
ates the effect of SSRI fluoxetine upon cell firing
in dorsal raphe nucleus: A concomitant electro-
physiological and electrochemical in vivo study re-
veals implications for modulating extracellular 5-
HT. Brain Res. 1334, 1-11.
Crespi F. (2010c) Further Electrochemical and Be-
havioural Evidence of a Direct Relationship Be-
tween Central 5-HT and Cytoskeleton in the Con-
trol of Mood. The Open Neurol. J. 4, 5-14.
Crespi F. (2010d) Is a divergent central serotonergic
activity responsible for either despair or learning
behavior in intact Wistar or Sprague-Dawley CD
rats, respectively? A concomitant behavioral and
electrochemical analysis. Psychology 1, 1-11.
Crespi F. (2009) Apamin increases 5-HT cell firing in
raphe dorsalis and extracellular 5-HT levels in
amygdala: a concomitant in vivo study in anaes-
thetized rats. Brain Res. 1281, 35-46.
Crespi F. (2007) Near-infrared spectroscopy (NIRS): a
non invasive in vivo methodology for analysis of
brain vascular and metabolic activities in real time
in rodents. Current Vascul. Pharmacol. 5(4), 305-
321.
Crespi F., Bandera A., Donini M. (2006) Near Infrared
Spectroscopy for the non-invasive assessment of
brain metabolism: An index of blood brain bar-
rier penetration? Monitoring Molecules in Neuro-
science. In vivo Methods 252-254.
Crespi F., Croce A., Fiorani S., Chem B. M., Hei-
dbreder C., Bottiroli G. (2004) Autofluorescence
Spectrofluorometry of CNS system neuromedia-
tors. Laser Surg. and Med. 34, 39-47.
Crespi F. (2002) In vivo voltammetry and concomitant
electrophysiology at a single biosensor to analyse
ischaemia, depression and drug dependence. J.
Neurosci. Meth. 119, 173-184.
Crespi F., Campagnola M., Neudeck A., McMillan,
K., Rossetti Z., Pastorino A., Garbin U., Fratta-
Pasini A., Reggiani A., Gaviraghi G., Cominaici
L. (2001) Can voltammetry measures nitrogen
monoxide (NO) and/or nitrites? J. Neurosci.
Meth. 109, 59-70.
Crespi F., Ratti E., Trist D. G. (1994) Melatonin, a hor-
mone monitorable in vivo by voltammetry? The
Analyst 119, 2193-2197.
Crespi F. (1991) In vivo voltammetry detection of neu-
ropeptides with micro carbon fibre biosensors: pos-
sibile selective detection of somatostatin. Anal.
Biochem. 194, 1-8.
Crespi F. (1990) In vivo voltammetry with micro-
biosensors for analysis of neurotransmitter release
and metabolism. J. Neurosci. Meth. 34, 53-65.
Crespi F., Martin K. F., Heal D. J., Marsden C. A.,
Buckett W. R., Sanghera M. K. (1989) Measure-
ment of 3 methoxytyramine by in vivo voltamme-
try: evidence for differences in cerebral dopamine
function in Balb/c and CBA mice. Brain Res. 500,
241-246.
Crespi F., Martin K. F., Marsden C. A. (1988) Nafion
coated carbon fibre electrodes combined with dif-
ferential pulse voltammetry measure 5HT release
in vivo. Neuroscience 27, 885-896.
Crespi F., Sharp T., Maidment N., Marsden C. A.
http://dx.medra.org/10.7423/XJENZA.2013.2.02 http://www.mcs.org.mt/
Serotonin, how to find it... 22
(1984) Differential Pulse Voltammetry: simultane-
ous in vivo measurement of ascorbic acid, catechols
and 5-hydroxyindoles in the rat striatum using a
single carbon fibre electrode. Brain Res. 322,135-
138.
Crespi F., Jouvet M. (1983a) Differential pulse voltam-
metry: parallel peak 3 changes with vigilance
states in raphe dorsalis and raphe magnus of
chronic freely moving rats and evidence for 5HT
contribution to this peak after monoamine oxidase
inhibitors. Brain Res. 272, 263-268.
Crespi F., Sharp T., Maidment N., Marsden C. A.
(1983b) Differential pulse voltammetry in vivo, ev-
idence that the uric acid contributes to the indole
oxidation peak. Neuroscience Letters 43, 203-207.
Dahlstrom A., Fuxe K. (1964) Evidence for the existence
of monoamine -containing neurones in the CNS. I.
Demonstration of monoamines in the cell bodies of
brain stem neurones. Acta Physiol. Scand. Suppl.
62, 1-55.
Falk B., Hillarp N. A., Thieme G., Torp, A. (1962) Fluo-
rescence of catecholamines and related compounds
condensed with formaldehyde. J. Histochem. Cy-
tochem. 10, 348-354.
Gaddum J. H. (1961) Push-pull cannulae. J. Physiol.
(London) 155, 1-2P.
Graeff F. G., Guimaraes F. S., De Andrade T. G.,
Deakin J. F. (1996) Role of 5-HT in stress, anxi-
ety, and depression. Pharmacol. Biochem. Behav.
54(1), 129-141.
Hamon M., Bourgoin S., el Mestikawy S., Goetz C.
(1982) Central serotonin receptors. Oxford: Black-
well Science. pp. 107-143.
Heyrovsky J. (1924) The processes at the mercury drop-
ping cathode. Part II. The hydrogen overpotential.
Trans. Faraday Soc. 19, 785-788.
Hyyppa M., Wurtman R. J. (1973) Biogenic amines in
the pituitary gland: what is their origin and func-
tion? Pituitary indolamines. Prog. Brain.Res. 39,
211-215.
Jacobs B. L., Azmitia E. C. (1992) Structure and func-
tion of the brain serotonin system. Physiol. Rev.
72, 165–229.
Khan A. S., Michael A. C. (2003) Invasive consequences
of using micro-electrodes and microdialysis probes
in the brain. TrAC Trends in Anal. Chem. 22(8),
503–508.
Marsden C. A., Conti J., Strope E., Curzon G., Adams,
R. (1979) Monitoring 5HT release in the brain of
the freely moving rat using in vivo voltammetry.
Brain. Res. 171, 85-99.
Meguid M. M., Fetissov S. O., Varma M., et al. (2000)
Hypothalamic dopamine and serotonin in the reg-
ulation of food intake. Nutrition 16, 843-857.
Peroutka S. J., Howell T. A. (1994) The molecular evo-
lution of G protein-coupled receptors: focus on 5-
hydroxytryptamine receptors. Neuropharmacology
33, 319-324.
Rapport M. M., Green A. A., Page I. H. (1948) Serum
vasoconstrictor (serotonin) IV. J. Biol. Chem.
176,1243-1251.
Rossetti Z., Crespi F. (2004) Inhibition of Nitric Oxide
release in vivo by ethanol. Alcohol. Clin. Exp.
Res. 28, 1746-1751.
Roth B. L., Hanizavareh S. M., Blum A. E. (2004)
Serotonin receptors represent highly favorable
molecular targets for cognitive enhancement in
schizophrenia and other disorders. Psychopharma-
cology (Berl) 174,17-24.
Saxena P. R. (1995) Serotonin receptors: subtypes,
functional responses and therapeutic relevance.
Pharmacol. Ther. 66, 339-368.
Stamford J., Crespi F., Marsden C. A. (1992) In vivo
voltammetric methods for monitoring monoamine
release and metabolism. In Practical Approach Se-
ries Monitoring Neuronal Activity. Irl. Press at
Oxford University Press: Oxford, U.K. pp.113-145.
Steinbush H. W. M. (1981) Distribution of 5HT-
immunoreactivity in the CNS of the rat-cell bodies
and terminals. Neurosci. 6, 557-618.
Twarog B. M., Page I. H. (1953) Serotonin content of
some mammalian tissues and urine and a method
for its dertermination. Am. J. Physiol. 175, 157-
161.
Ungerstedt, U. (1984) Measurement of neurotransmitter
release by intracranial dialysis. In: Measurement
of Neurotransmitter Release in vivo pp 81-105. Ed.
C.A. Marsden. John Wiley & Sons, Chichester,
UK.
Ursin R. (2002) Serotonin and sleep. Sleep Med.Rev. 6
(1), 57–69.
Udenfriend S. (1962) Fluorescence Assay in Biology and
Medicine. Molecular Biology. An International
Series of Monographs and Textbooks. New York,
London: Academic Press 55, 216.
Van de Kar L. D. (1991) Neuroendocrine pharmacol-
ogy of serotonergic (5-HT) neurons. Annu. Rev.
Pharmacol. Toxicol. 31, 289-320.
Vialli M., Erpsamer V. (1933) Cellule enterocromaffini e
cellule basi-granulose acidofile nei vertebrati. Zis-
chr. Zellforsch. U. Mikr. Anat. 19, 743-745.
Yaksh T. L., Yamamura H. I. (1974) Factors affecting
performance of the push pull cannulae in brain. J.
Appl. Physiol. 37, 428-434.
http://dx.medra.org/10.7423/XJENZA.2013.2.02 http://www.mcs.org.mt/
